Talking About Current Stock Valuation: Hemispherx Biopharma, Inc. (HEB), CenturyLink, Inc. (CTL) – Post Analyst

This post was originally published on this site

Talking About Current Stock Valuation: Hemispherx Biopharma, Inc. (HEB), CenturyLink, Inc. (CTL)  Post Analyst

Hemispherx Biopharma, Inc. (NYSE:HEB), with a trailing 12-month price-to-sales ratio of 30.61, is now among the bigger bargains in its industry. The broad …

This post was originally published on *this site*